Free Trial

Privia Health Group (PRVA) Stock Forecast & Price Target

$19.17
+0.07 (+0.37%)
(As of 07/19/2024 ET)

Privia Health Group - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 14 Wall Street analysts who have issued ratings for Privia Health Group in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 2 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for PRVA.

Consensus Price Target

$24.54
28.00% Upside
High Forecast$30.00
Average Forecast$24.54
Low Forecast$19.00

According to the 14 analysts' twelve-month price targets for Privia Health Group, the average price target is $24.54. The highest price target for PRVA is $30.00, while the lowest price target for PRVA is $19.00. The average price target represents a forecasted upside of 28.00% from the current price of $19.17.

TypeCurrent Forecast
7/21/23 to 7/20/24
1 Month Ago
6/21/23 to 6/20/24
3 Months Ago
4/22/23 to 4/21/24
1 Year Ago
7/21/22 to 7/21/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
11 Buy rating(s)
8 Buy rating(s)
13 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$24.54$24.92$28.18$38.63
Forecasted Upside28.00% Upside27.53% Upside30.52% Upside31.79% Upside
Get Privia Health Group Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PRVA and its competitors with MarketBeat's FREE daily newsletter.

PRVA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PRVA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Privia Health Group Stock vs. The Competition

TypePrivia Health GroupMedical CompaniesS&P 500
Consensus Rating Score
2.93
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside28.00% Upside1,426.46% Upside10.03% Upside
News Sentiment RatingVery Positive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/9/2024Evercore ISI
2 of 5 stars
 Lower TargetOutperform ➝ Outperform$23.00 ➝ $20.00+18.69%
5/30/2024Baird R W
0 of 5 stars
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/30/2024Robert W. Baird
2 of 5 stars
 Initiated CoverageOutperform$23.00+40.24%
5/20/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$22.00 ➝ $19.00+14.53%
5/15/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$28.00 ➝ $24.00+34.30%
5/10/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$37.00 ➝ $26.00+44.36%
5/1/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$28.00 ➝ $24.00+30.43%
4/22/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$25.00+38.27%
3/6/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$38.00 ➝ $30.00+41.38%
3/1/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$31.00 ➝ $29.00+31.28%
3/1/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$30.00 ➝ $26.00+16.49%
2/26/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$33.00 ➝ $25.00+25.63%
2/22/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$27.00 ➝ $21.00+2.79%
12/6/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$27.00+29.19%
5/5/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$39.00 ➝ $40.00+38.70%
4/11/2023Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$33.00+17.61%
3/9/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$36.00+29.87%
3/7/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$41.00+44.26%
2/3/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$32.00+15.52%
1/9/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$45.00 ➝ $40.00+85.96%
11/17/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$42.00+77.97%
11/11/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$46.00 ➝ $39.00+36.70%
8/12/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$36.00 ➝ $51.00+33.40%
8/12/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$35.00 ➝ $44.00+16.19%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:41 PM ET.

PRVA Forecast - Frequently Asked Questions

What is Privia Health Group's forecast for 2024?

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Privia Health Group is $24.54, with a high forecast of $30.00 and a low forecast of $19.00.

Should I buy or sell Privia Health Group stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Privia Health Group in the last year. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PRVA shares.

Does Privia Health Group's stock price have much upside?

According to analysts, Privia Health Group's stock has a predicted upside of 28.08% based on their 12-month stock forecasts.

Has Privia Health Group been upgraded by Wall Street analysts recently?

Over the previous 90 days, Privia Health Group's stock had 1 upgrade by analysts.

What analysts cover Privia Health Group?

Privia Health Group has been rated by research analysts at Baird R W, Barclays, Canaccord Genuity Group, Citigroup, Evercore ISI, Robert W. Baird, Stifel Nicolaus, and Truist Financial in the past 90 days.

Do Wall Street analysts like Privia Health Group more than its competitors?

Analysts like Privia Health Group more than other "medical" companies. The consensus rating score for Privia Health Group is 2.93 while the average consensus rating score for "medical" companies is 2.72. Learn more on how PRVA compares to other companies.


This page (NASDAQ:PRVA) was last updated on 7/20/2024 by MarketBeat.com Staff

From Our Partners